跳至主要内容
临床试验/NCT02926976
NCT02926976Unknown不适用

The Optimal Treatment for Treatment-resistant Schizophrenia

Shanghai Mental Health Center1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2016年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
150
试验地点
1
主要终点
Change from baseline in Positive and Negative Syndrome Scale [PANSS]

研究概览

简要总结

The Optimal Treatment for Treatment-resistant Schizophrenia

详细描述

To explore the curative effect and safety of Risperidone,aripiprazole,sodium valproate,modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia, and to provide the basis for clinical medication.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • The diagnosis of schizophrenia according to DSM-V
  • 18~60 years old
  • 2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration;
  • Signed an informed consent

排除标准

  • patients to be diagnosed according to DSM-V for substance abused, development delayed
  • suffering from serious physical disease and can not accept the treatment
  • MST contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure
  • allergic to risperidone ,aripiprazole, or sodium valproate
  • Participated in any clinical subject within 30 days
  • Pregnancy or lactation

研究组 & 干预措施

risperidone with clozapine

Active Comparator

risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks

干预措施: Risperidone with Clozapine (Drug)

aripiprazole with clozapine

Active Comparator

aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks

干预措施: Aripiprazole with Clozapine (Drug)

sodium valproate with clozapine

Active Comparator

sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.

干预措施: sodium valproate with Clozapine (Drug)

clozapine

Active Comparator

only clozapine, dosage and frequency:300~600 mg/d;

干预措施: clozapine (Device)

Modified electroconvulsive therapy with clozapine

Active Comparator

10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.

干预措施: modified electroconvulsive therapy(MECT) with Clozapine (Device)

Magnetic seizure therapy with clozapine

Active Comparator

10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.

干预措施: Magnetic seizure therapy(MST) with Clozapine (Device)

结局指标

主要结局

Change from baseline in Positive and Negative Syndrome Scale [PANSS]

时间窗: At baseline, 4th week, 8th week,12th week

次要结局

  • Change from baseline in clinical global impression [CGI](At baseline, 4th week, 8th week,12th week)
  • Change from baseline in Abnormal Involuntary Movement Scale[AIMS](At baseline, 4th week, 8th week,12th week)
  • Change from baseline in Simpson-Angus Scale [SAS](At baseline, 4th week, 8th week,12th week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验